Goldman Sachs Upgrades Protagonist Therapeutics to Buy, Raises Price Target to $186

Benzinga Newsdesk www.benzinga.com Positive 80.3%

Neg 0% Neu 0% Pos 80.3%

Goldman Sachs analyst Richard Law upgrades Protagonist Therapeutics (NASDAQ:PTGX) from Neutral to Buy and raises the price target from $110 to $186.